Concurrently, IL-17A enhances CXCL5 production in tumor cells and promotes MDSC migration at the tumor site through a CXCR2-dependent mechanism, facilitating tumor progression and immune evasion [95]. This evidence concerns the gene CXCR2 and neoplasm.